欧美自拍另类欧美宗合图片区,国产视频一区二区三区四区,日本一区二区三区四区视频,婬片一区AAA毛片一区二区

商品編號


AG-20T-0308-C100



品牌


Adipogen



公司


Adipogen



公司分類(lèi)


Antibodies



Size

100 ?g

商品信息


More Information



Product Details



Synonyms

Toll-like Receptor 9; CD289



Product Type

Monoclonal Antibody



Properties



Clone

ABM1C51



Isotype

Mouse IgG1κ



Immunogen/Antigen

Recombinant human TLR9 protein (aa 100-290).



Application


Flow Cytometry:
(0.5μg/10
6
cells)
Immunohistochemistry:
(5μg/ml; paraffin sections)
Western Blot:
(2-4μg/ml)
Optimal conditions must be determined individually for each application.



Crossreactivity

Human
Mouse



Specificity

Recognizes human and mouse TLR9.



Purity

Protein G purified.



Concentration

0.5mg/ml



Formulation

Liquid. In PBS containing 0.05% BSA and 0.05% sodium azide.



Accession Number

Q9NR96



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.
Stable for at least 6 months after receipt when stored at +4°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





TLR9 (Toll-like Receptor 9) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 is expressed by numerous cells of the immune system such as B lymphocytes, monocytes, natural killer (NK) cells and plasmacytoid dendritic cells. It is expressed intracellularly, within the endosomal compartments and functions to alert the immune system of viral and bacterial infections by binding to DNA rich in CpG motifs. This nucleotide-sensing TLR is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (also called oligodinucleotides, ODNs), and consequently signals via MYD88 and TRAF6, le
ADI
ng to NF-κB activation, cytokine secretion and the inflammatory response and eventually activation of a Th1-biased adaptive immune attack. Specific TLR9 ago
NIST
s have been shown to have substantial antitumor activity, making the TLR9 signaling pathway an interesting target for therapeutic research.